The evaluation of isotretinoineffects on treatment of COVID-19 infections

Phase 3

• Conditions: Covid-19.; Virus identified; U07.1

• Registration Number: IRCT20190624043993N3
• Lead Sponsor: Kermanshah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Positive covid-19 test
During first 48 hours of symptoms

Exclusion Criteria

Underlying hematologic disease
Underlying liver disease
Known allergy to Isotretinoin
Pregnancy/lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Cure. Timepoint: Seven and 14 days after treatment initiation. Method of measurement: Clinical and laboratory evaluations.;Virological cure. Timepoint: Day 7. Method of measurement: PCR.;ABG findings. Timepoint: Day 7. Method of measurement: Laboratory assessment.

Secondary Outcome Measures

Name	Time	Method
Radiological cure, organ dysfunction, death. Timepoint: Day 14. Method of measurement: Clinical and para-clinical data.;Organ dysfunction. Timepoint: Day 7. Method of measurement: Clinical and laboratory data.;Death. Timepoint: Day 28. Method of measurement: Observation.